Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours

Internal Medicine Journal
M KhasrawN Pavlakis

Abstract

Conventional cytotoxic chemotherapy is not usually effective in neuroendocrine tumours (NET). Somatostatin analogues (SSA) such as octreotide (Sandostatin; octreotide LAR and lanreotide) are typically used to treat symptoms caused by NET, but not as the primary treatment aiming for an objective response. Recently, results from the PROMID (Placebo-controlled prospective Randomized study on the antiproliferative efficacy of Octreotide LAR in patients with metastatic neuroendocrine MIDgut tumours) trial were published showing that octreotide LAR significantly lengthens the time to tumour progression compared with a placebo in patients with functionally active and inactive metastatic midgut NET. We report a retrospective descriptive analysis of six patients, treated at two Australian institutions, who obtained an objective radiological tumour response on long acting SSA. In this retrospective series of NET, radiological responses were observed using single agent SSA, which was administered mainly for symptom management. This could be due to an antiproliferative and/or antiangiogenic activity of this agent in NET. A response can occur beyond 12 months, which might explain why the response rate is under reported in NET trials. Furthe...Continue Reading

References

Jan 1, 1993·Acta Oncologica·L AnthonyJ Oates
Dec 24, 1997·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B ErikssonK Oberg
Jul 10, 1999·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B Eriksson, K Oberg
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Siegbert FaissUNKNOWN International Lanreotide and Interferon Alfa Study Group
Oct 20, 2005·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Rudolf ArnoldChristian N Arnold
Jul 11, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C Carl Jaffe
Jan 8, 2008·The Lancet Oncology·Irvin M ModlinAnders Sundin

❮ Previous
Next ❯

Citations

Jan 26, 2016·Expert Review of Anticancer Therapy·Mustafa KhasrawMichael Michael
Sep 1, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Ina RosenbergerJörg Kreuter
Apr 9, 2013·Expert Review of Anticancer Therapy·Mustafa KhasrawSumitra Ananda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.